Redhill Biophrma ADR (RDHL)

$0.87 -0.01 (-1.14%)
Market Cap 4.50M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 8,900
Avg Vol 576,988
Day's Range N/A - N/A
Shares Out 5.11M
Stochastic %K 41%
Beta 4.91
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
kayley28
kayley28 Mar. 12 at 3:47 PM
$RDHL dont trust anything from isrel
0 · Reply
Patrick2343
Patrick2343 Mar. 10 at 5:05 PM
$RDHL Fresh new 52 week lows and we be out of compliance once again soon. Notice they do not even attemp pump and dumbs anymore I guess they ran out of stuff to pump with.
1 · Reply
kayley28
kayley28 Mar. 6 at 3:00 PM
$RDHL Dror Ben-Asher salary is $566,000 ~ $595,000 lol
1 · Reply
focafoca99
focafoca99 Mar. 4 at 11:41 PM
$RDHL The key now is whether commercial execution captures that growth trend instead of just talking about it.
0 · Reply
therealchorris
therealchorris Mar. 4 at 6:25 PM
$RDHL It could not get worse even if an Iranian missile did a direct hit on their HQ.
0 · Reply
Patrick2343
Patrick2343 Mar. 2 at 7:43 PM
$RDHL the stock is literally in the toilet and all they want to do is dilute over and over again. This company is nothging but a scam.
0 · Reply
Kosmokrat
Kosmokrat Feb. 27 at 2:17 PM
$RDHL Looks like more dilution coming our way. There will be an extraordinary shareholder meeting on Mar-5 to approve the following: 1. To approve the grant of restricted share units (“RSUs”) (...) to the non executive directors of the Company; 2. To approve the grant of RSUs to Mr. Dror Ben-Asher, (...) 3. To approve the grant of RSUs to Mr. Rick D. Scruggs, (...) 4. To approve an increase in the Company’s authorized share capital.
0 · Reply
tatanka9
tatanka9 Feb. 26 at 2:23 AM
$RDHL REDSCAM Alert!!!
0 · Reply
Isaaccs
Isaaccs Feb. 25 at 10:53 PM
$RDHL There are no news that could make up the probable dilution.
0 · Reply
therealchorris
therealchorris Feb. 25 at 3:49 PM
$RDHL Sentiment is bullish, but no movement on positive news 🤷🏼‍♂️
0 · Reply
Latest News on RDHL
Joint U.S. Commercialization of RedHill's Talicia® Commences

Feb 25, 2026, 7:00 AM EST - 16 days ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

CPIX

What's Going On With Redhill Biopharma Stock On Tuesday?

Jan 6, 2026, 10:26 AM EST - 2 months ago

What's Going On With Redhill Biopharma Stock On Tuesday?

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Jan 5, 2026, 7:00 AM EST - 2 months ago

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Dec 15, 2025, 7:00 AM EST - 3 months ago

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Dec 1, 2025, 7:00 AM EST - 3 months ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Nov 4, 2025, 9:30 AM EST - 4 months ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 22, 2025, 4:50 PM EDT - 5 months ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Oct 6, 2025, 8:00 AM EDT - 5 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 29, 2025, 7:00 AM EDT - 5 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Sep 5, 2025, 7:00 AM EDT - 6 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 7 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 7 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 8 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 9 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 10 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 11 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 11 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 11 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 11 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 1 year ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 1 year ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 1 year ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 1 year ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 1 year ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 2 years ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 2 years ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

kayley28
kayley28 Mar. 12 at 3:47 PM
$RDHL dont trust anything from isrel
0 · Reply
Patrick2343
Patrick2343 Mar. 10 at 5:05 PM
$RDHL Fresh new 52 week lows and we be out of compliance once again soon. Notice they do not even attemp pump and dumbs anymore I guess they ran out of stuff to pump with.
1 · Reply
kayley28
kayley28 Mar. 6 at 3:00 PM
$RDHL Dror Ben-Asher salary is $566,000 ~ $595,000 lol
1 · Reply
focafoca99
focafoca99 Mar. 4 at 11:41 PM
$RDHL The key now is whether commercial execution captures that growth trend instead of just talking about it.
0 · Reply
therealchorris
therealchorris Mar. 4 at 6:25 PM
$RDHL It could not get worse even if an Iranian missile did a direct hit on their HQ.
0 · Reply
Patrick2343
Patrick2343 Mar. 2 at 7:43 PM
$RDHL the stock is literally in the toilet and all they want to do is dilute over and over again. This company is nothging but a scam.
0 · Reply
Kosmokrat
Kosmokrat Feb. 27 at 2:17 PM
$RDHL Looks like more dilution coming our way. There will be an extraordinary shareholder meeting on Mar-5 to approve the following: 1. To approve the grant of restricted share units (“RSUs”) (...) to the non executive directors of the Company; 2. To approve the grant of RSUs to Mr. Dror Ben-Asher, (...) 3. To approve the grant of RSUs to Mr. Rick D. Scruggs, (...) 4. To approve an increase in the Company’s authorized share capital.
0 · Reply
tatanka9
tatanka9 Feb. 26 at 2:23 AM
$RDHL REDSCAM Alert!!!
0 · Reply
Isaaccs
Isaaccs Feb. 25 at 10:53 PM
$RDHL There are no news that could make up the probable dilution.
0 · Reply
therealchorris
therealchorris Feb. 25 at 3:49 PM
$RDHL Sentiment is bullish, but no movement on positive news 🤷🏼‍♂️
0 · Reply
topstockalerts
topstockalerts Feb. 25 at 1:46 PM
$RDHL strong watch at these levels
0 · Reply
batmantradingzz
batmantradingzz Feb. 25 at 1:18 PM
$ADVB $UOKA $RETO $RDHL Advb heating up ⏰️🌋
0 · Reply
topstockalerts
topstockalerts Feb. 25 at 1:07 PM
$RDHL look who’s waking up..
0 · Reply
batmantradingzz
batmantradingzz Feb. 25 at 12:28 PM
$ADVB 580k float 2k shortshares available Crazy setup Bottom low risk nice reward $UOKA watching $RETO nice $RDHL
0 · Reply
TA_Kongen
TA_Kongen Feb. 25 at 12:11 PM
$RDHL Headline not bad here but mkt is shot. Will keep on watch.
0 · Reply
Balmus
Balmus Feb. 25 at 12:11 PM
$RDHL Joint U.S. Commercialization of RedHill's Talicia® Commences--https://www.prnewswire.com/news-releases/joint-us-commercialization-of-redhills-talicia-commences-302696888.html
0 · Reply
BullModeOn
BullModeOn Feb. 25 at 12:08 PM
Morning watchlist $XWEL $RDHL $HCWC $UOKA $QNCX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 1:09 AM
$RDHL RSI: 35.87, MACD: -0.0650 Vol: 0.12, MA20: 1.08, MA50: 1.17 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JISVI
JISVI Feb. 24 at 12:12 PM
$RDHL https://www.ad-hoc-news.de/boerse/news/ueberblick/redhill-biopharma-charts-new-strategic-course-with-key-shareholder-vote/68607105
0 · Reply
cryptoish
cryptoish Feb. 19 at 2:41 PM
$RDHL delist this bullshit. And oh yeah , rot in hell ! Fcking genocide company
0 · Reply
FrankScott130
FrankScott130 Feb. 18 at 2:00 PM
$RDHL Biotech with clinical setbacks risk.
0 · Reply
sweepjosh
sweepjosh Feb. 17 at 8:42 AM
$RDHL Micro-cap biotech; commercial-stage
0 · Reply